Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study - Bahlis, Nizar J.; Dimopoulos, Meletios A.; White, Darrell J.; Benboubker, Lotfi; Cook, Gordon; Leiba, Merav; Ho, P. Joy; Kim, Kihyun; Takezako, Naoki; Moreau, Philippe; Kaufman, Jonathan L.; Krevvata, Maria; et al. (Leukemia, 2020)
Keywords: 631/67; 692/308; Aged; Antibodies, Monoclonal - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; B cells; Cancer Research; Critical Care Medicine; Development and progression; Dexamethasone; Dexamethasone - administration & dosage; Drug Resistance, Neoplasm - drug effects; Female; Follow-Up Studies; Health risks; Hematology; Humans; Immunotherapy; Intensive; Internal Medicine; Lenalidomide - administration & dosage; Male; Medical research; Medicine; Medicine & Public Health; Medicine, Experimental; Minimal residual disease; Monoclonal antibodies; Multiple myeloma; Multiple Myeloma - drug therapy; Multiple Myeloma - pathology; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - pathology; Next-generation sequencing; Oncology; Pharmaceutical industry; Prognosis; Risk assessment; Safety; Salvage Therapy; Schedules; Steroids; Subgroups; Survival Rate; Targeted cancer therapy; Thalidomide - administration & dosage; United States